Showing results (441-450 of 974) with videos related to

Sort By:
Pageof 98
Cancer Research|January 8, 2014
A reevaluation of CD22 expression in human lung cancerLaurentiu M Pop, Stephen Barman, Chunli Shao, et al.
Journal of Medicinal Chemistry|April 4, 1998
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activitiesD E Bierer, D M Fort, C D Mendez, et al.
Research Square|December 8, 2025
Tobacco use and perceived risk of lung cancer in a safety-net populationMary E Gwin, Heidi A Hamann, Tanushree Prasad Ma, et al.
Nature Cancer|December 3, 2020
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancerKe Gong, Gao Guo, Nishah Panchani, et al.
JCI Insight|August 4, 2017
Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan miceRosanne Rouf, Elena Gallo MacFarlane, Eiki Takimoto, et al.
British Journal of Cancer|October 16, 2018
Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosisDavid E Gerber, M Shaalan Beg, Farjana Fattah, et al.
CA: a Cancer Journal for Clinicians|June 2, 2022
Oncologic emergencies and urgencies: A comprehensive reviewBonnie E Gould Rothberg, Tammie E Quest, Sai-Ching J Yeung, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
JCO Clinical Cancer Informatics|March 7, 2025
Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 PandemicMary E Gwin, Urooj Wahid, Sheena Bhalla, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Pageof 98